GHK-Cu

01 · What it is

GHK is the tripeptide glycyl-L-histidyl-L-lysine, molecular weight approximately 340 Da. GHK-Cu is its complex with copper(II), molecular weight approximately 404 Da. Unlike most compounds in this family it is a genuine endogenous constituent of human plasma, and its chemistry — high-affinity copper binding — is among the best defined of any molecule discussed on this site.

It was identified in 1973 by Pickart and Thaler in a paper whose title states exactly what the experiment showed: a tripeptide in human serum that prolongs survival of normal liver cells and stimulates growth in neoplastic liver ¹. In 1980 the same investigators established the mechanistic core. GHK associates in vivo with copper and iron; at physiological pH it binds copper, cobalt, iron, molybdenum, manganese, nickel and zinc but not calcium, potassium or sodium; and its effects on hepatoma cell cultures appear to be exerted as a peptide–metal chelate rather than by the free peptide ². GHK-Cu is, mechanistically, a copper carrier.

The literature since is unusual in two ways. It is long — fifty-three years — and it is dominated by one investigator, who discovered the molecule and has authored the majority of its review literature into the present ^1,2,3,5,7.

The human evidence does not match the length of the record. A search of the indexed literature for this guide found one randomised controlled trial of GHK-Cu on human skin. It enrolled thirteen completers, and it was negative on every objective endpoint it measured: no significant difference in resolution of post-treatment erythema by computer analysis or blinded evaluators, and no significant difference between groups in wrinkles or overall skin quality. Only the patient questionnaire differed, favouring GHK-Cu (P = .04) ³. Separately, GHK-Cu is hydrophilic and permeates the stratum corneum poorly, which is the central unsolved problem for topical delivery ¹².

As of September 2026 GHK-Cu holds no marketing authorisation as a drug in any jurisdiction. It is widely used as a cosmetic ingredient, which is a different regulatory pathway.

02 · Evidence at a glance

Evidence grade

Mixed Evidence

Years since first publication

53 ¹

Molecular identity

Endogenous human plasma tripeptide; copper(II) chelate ^1,2

Molecular target

No receptor identified. Mechanism is metal chelation and delivery ²

Randomised controlled trials on human skin, indexed

1 ³

Completers in that trial

13

Objective endpoints met

None ³

Subjective endpoint met

Yes — patient-reported skin quality, P = .04 ³

Human studies of injected GHK-Cu

None identified

Human pharmacokinetic data

None identified, topical or injected

Principal delivery obstacle

Poor stratum corneum permeation; hydrophilic compound ^11,12

Research concentration

High — the discoverer authors the majority of the review literature ^1,2,5,7

Approval status as a drug

None, any jurisdiction

03 · Mechanism of action

Copper chelation and delivery — the part that is settled

GHK binds Cu(II) with high affinity and circulates complexed with transition metals; in cell culture the metal complexes, not the free peptide, account for the observed effects on adhesion and growth ². This is coordination chemistry, it was established early, and it has not been seriously contested. Copper is a required cofactor for lysyl oxidase, which cross-links collagen and elastin, and for superoxide dismutase. The most defensible account of GHK-Cu’s activity is therefore indirect: it moves copper to where copper-dependent enzymes are, and the downstream effects are copper’s. Commentary from investigators outside the originating group describes the same picture — high copper affinity, with anti-inflammatory and tissue-remodelling properties attributed to both the peptide and its chelate ⁸.

Extracellular matrix remodelling

Reported effects include modulation of collagen, elastin, proteoglycan and glycosaminoglycan synthesis in dermal fibroblast systems, and modulation of matrix metalloproteinases and their inhibitors ^4,5. In a 2023 fibroblast and ex vivo skin study, GHK-Cu combined with low-molecular-weight hyaluronic acid at a 1:9 ratio increased collagen IV synthesis relative to controls, with the combination outperforming either component ⁹. That is a real, independent, mechanistically specific result — and it is an in vitro and ex vivo result testing a formulation.

The gene expression claim, and what kind of evidence it is

The most-repeated modern claim is that GHK modulates a large number of human genes, and it derives from analysis of gene expression datasets rather than from measurement in treated human tissue ^5,7. Pattern-matching a compound’s signature against expression databases generates hypotheses; it does not demonstrate that administering the compound produces those changes in skin. The distinction matters because this analysis, more than any experiment, is what elevated GHK-Cu’s reputation over the last decade.

Angiogenesis and cell recruitment in animals

Animal wound models report increased angiogenesis and proliferation, with increased CD31 and Ki67 signal in treated tissue ⁶. The design of the most-cited such study is worth noting: it compared GHK-Cu delivered in liposomes against free GHK-Cu, and the liposomal preparation performed better ⁶. That tests the carrier as much as the peptide, and it is consistent with permeation being the limiting factor.

No receptor, and no need for one

Unlike BPC-157, the absence of an identified receptor is not obviously a gap here. If the mechanism is copper delivery, a receptor is not required — the peptide is a shuttle, not a ligand. But that framing carries its own consequence, addressed in Limitations: an effect attributable to copper delivery raises the question of what copper alone, or another copper carrier, would do, and the literature contains few such comparisons.

04 · Key research findings

Human skin, controlled evidence. Patients undergoing circumoral carbon dioxide laser resurfacing were randomised to post-treatment regimens with or without GHK-Cu-containing products. Thirteen completed. Erythema was assessed by computer image analysis and by blinded evaluators; wrinkles and overall skin quality were assessed at twelve weeks; patients completed a validated questionnaire before and after. No statistically significant difference between groups was found for resolution of erythema. All patients improved in wrinkles and overall skin quality, with no difference between groups. The questionnaire showed a significant difference favouring GHK-Cu for post-treatment improvement in overall skin quality (P = .04) ³.

This is the highest-quality human evidence that exists for GHK-Cu, it used objective and blinded assessment, and it found an effect only on what patients reported about themselves.

Human skin, uncontrolled and unindexed evidence. The twelve-week facial and eye-cream studies that appear in most accounts of this compound could not be verified to a primary indexed source during preparation of this guide. They are therefore not cited here, and claims that trace only to them should be treated as unverified.

A fifty-three-year-old compound whose most-quoted human results cannot be located in the indexed literature is telling the reader something.

Delivery and permeation. GHK-Cu is hydrophilic with limited permeation through the lipophilic stratum corneum, and reviews of its topical use treat delivery as the central unsolved problem ^11,12. Liposomal and other carrier systems are under active investigation for exactly this reason ^6,10, and methods for measuring permeation of encapsulated GHK-Cu are themselves still being developed ¹².

A compound that struggles to cross the outer skin barrier cannot be assumed to reach dermal fibroblasts at the concentrations that produce effects in culture — which is the single most important caveat on the entire in vitro literature.

In vitro matrix effects. GHK-Cu with low-molecular-weight hyaluronic acid increased collagen IV synthesis in fibroblast and ex vivo skin tests, with a defined optimal ratio ⁹. Broader reviews collect reported effects on collagen, elastin, proteoglycans and metalloproteinase regulation ^4,5.

Independent groups reproduce matrix effects in culture; nobody has shown them in human skin under controlled conditions.

Animal wound healing. In a mouse scald model, liposomal GHK-Cu accelerated healing relative to free GHK-Cu, with increased angiogenesis and proliferation markers ⁶.

Consistent with a formulation effect at least as much as a peptide effect.

Foundational cell biology, and an uncomfortable detail. The 1973 discovery paper reported that the tripeptide prolonged survival of normal liver cells and stimulated growth in neoplastic liver ¹, and the 1980 mechanistic paper studied stimulation of adhesion and growth in a tumorigenic hepatoma cell line ².

The founding experiments for this compound were growth-stimulation experiments in cancer cells, and no subsequent work has examined what that implies for systemic administration.

Musculoskeletal claims. Recent reviews written for orthopaedic and sports medicine audiences include GHK-Cu among peptides with mechanistic rationale and unvalidated clinical benefit ^13,14.

No controlled human musculoskeletal study of GHK-Cu was identified.

05 · Evidence overview

06 · Safety profile

Animal data. No systematic toxicology programme for GHK-Cu was identified in the indexed literature. The animal work is efficacy-focused, principally rodent wound models, and does not report toxicological endpoints ⁶. Copper itself is a well-characterised element with dose-dependent systemic toxicity, and no published GHK-Cu study quantifies the copper load delivered by a given administration.

Human data. Topical cosmetic exposure has a long history without a signal of serious harm appearing in the indexed literature, and the one randomised trial reported no safety concerns among thirteen completers over twelve weeks ³. Both statements are weaker than they sound: absence of published reports is not a safety study, and topical exposure is superficial, intermittent and low-dose.

What is genuinely unknown. Systemic exposure and copper accumulation from injected use — no human data exist for that route at all. Behaviour in people with disordered copper handling. Effects of repeated administration by any route over months. Immunogenicity. Whether the compound reaches dermal targets at concentrations resembling those used in culture, which permeation work suggests may not be the case ^11,12. And the question raised by the compound’s own origin: the 1973 and 1980 foundational papers describe growth stimulation in hepatoma cells ^1,2, a peptide that increases angiogenesis and proliferation has an obvious theoretical risk profile in the presence of malignancy, and no published study has addressed it for systemic administration in humans.

07 · US regulatory status

Current as of 6 September 2026. GHK-Cu is not approved as a drug in the United States or any other jurisdiction, and is not a controlled substance. Its regulatory position is split by route.

As a cosmetic ingredient, GHK-Cu appears in commercially available topical products. Cosmetics in the United States are not subject to pre-market approval, and a product may not lawfully be marketed with claims that it affects the structure or function of the body — such claims would make it a drug.

As an injectable bulk drug substance, GHK-Cu was placed in category 2 of FDA’s interim compounding policy, and as of FDA’s page dated 22 April 2026 the entry for injectable routes appears in the table of substances nominated but subsequently withdrawn by the nominators ¹⁵. GHK-Cu was not among the seven substances reviewed by FDA’s Pharmacy Compounding Advisory Committee on 23–24 July 2026, which covered BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon ¹⁶. No agency evidence review of comparable depth exists for this compound.

Under the World Anti-Doping Code, substances not approved by any governmental regulatory health authority for human therapeutic use fall within category S0 and are prohibited at all times.

08 · Limitations of the evidence

1. The best human trial was negative on everything objective. A randomised, blinded, instrument- assessed study found no effect on erythema, wrinkles or skin quality; only self-reported satisfaction differed ³. This result is rarely mentioned in accounts of this compound, and it is the most important human datapoint that exists.

1. That trial enrolled thirteen completers. It is underpowered and cannot exclude a modest effect. The honest reading is that the question is open, not that GHK-Cu was shown ineffective — and after fifty-three years, an open question of this size is itself a finding.

1. The most-cited human studies cannot be verified. The twelve-week facial and eye-cream trials quoted in nearly every account could not be located in the indexed literature and are not cited here. Claims resting solely on them are unsupported until a primary source is produced.

1. Research concentration is unusually high. One investigator discovered the molecule in 1973 and has authored the dominant reviews since ^1,2,5,7. Independent groups have reproduced in vitro and animal effects ^6,9, but the interpretive framework around the compound comes largely from a single source.

1. Permeation may invalidate the translation from culture to skin. GHK-Cu is hydrophilic and crosses the stratum corneum poorly ^11,12. Concentrations that alter fibroblast behaviour in a dish may be unreachable in dermis through intact skin, which would explain the gap between consistent in vitro findings and a negative controlled trial.

1. Formulation confounds the animal evidence. The clearest animal result compared liposomal GHK-Cu against free GHK-Cu ⁶. When a carrier outperforms the free compound, the experiment has measured the carrier as much as the peptide.

1. The gene-expression claims are bioinformatic. Reported modulation of large numbers of human genes derives from database analysis rather than measurement in treated tissue ^5,7, and is hypothesis-generating rather than demonstrative.

1. The copper question is unaddressed in two directions. No study quantifies systemic copper exposure from injected GHK-Cu; and if the mechanism is copper delivery ², few experiments compare GHK-Cu against copper alone or another carrier, which is the control that would isolate the peptide’s contribution.

09 · References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85–87.

   PMID 4349963 ↗

2. Pickart L, Thaler MM. Growth-modulating tripeptide (glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol. 1980;102(2):129–139.

   PMID 6246126 ↗

3. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252–259.

   PMID 16847171 ↗

4. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988.

   PMID 18644225 ↗

5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.

   PMID 26236730 ↗

6. Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017;25(2):270–278.

   PMID 28370978 ↗

7. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.

   PMID 29986520 ↗

8. Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58–61.

   PMID 35083444 ↗

9. Jiang F, Wu Y, Liu Z, Hong M, Huang Y. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. J Cosmet Dermatol. 2023;22(9):2598–2604.

   PMID 37062921 ↗

10. Dymek M, Olechowska K, Hąc-Wydro K, Sikora E. Liposomes as carriers of GHK-Cu tripeptide for cosmetic application. Pharmaceutics. 2023;15(10):2485.

    PMID 37896245 ↗

11. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts. 2024;15:30071.

    PMID 39963574 ↗

12. Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M. Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes? Molecules. 2025;30(1):136.

    PMID 39795193 ↗

13. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236.

    PMID 41490200 ↗

14. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026; online ahead of print.

    PMID 42578445 ↗

15. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

16. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗